Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

JAMA Oncol. 2021 Aug 11;e214390. doi: 10.1001/jamaoncol.2021.4390. Online ahead of print.

Abstract

This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.